iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
AI is being applied to distinct parts of drug research: ranking targets and molecules, proposing biologic designs, screening for off-target interactions, searching institutional knowledge, and supporting clinical-trial work. These uses are not equivalent. A model’s ranked hits or a company’s pipeline count does not establish that an AI-designed medicine is safe, effective, or approved.
AI Weekly’s 2026 overview labels 15 examples as deployments and classifies 10 as in production or having results, with six reporting an outcome. That is the page’s editorial classification, not an independently audited census. The examples below focus on workflows for which the available source descriptions provide specific details.
What does the “15 deployments” count mean?
AI Weekly’s 2026 overview spans science and research, pharma and biotech, software, government, healthcare, and other fields. Its count therefore should not be read as 15 independently verified drug-discovery systems. The available case descriptions do not independently establish every deployment or confirm the overview’s production and outcome labels.
Do these 3 things before closing this tab:
1Fix the driver behind crashes, sound loss and screen glitches2Repair Windows errors before they cause bigger problems3Scan for outdated or missing drivers - takes under a minute“In production,” “pilot,” and “reported result” describe different levels of maturity. A report that a system is being used in a workflow does not necessarily show that it changed a scientific decision; a result on a computational screening task does not show that a medicine works in people. Where a source is a company or its technology vendor, its operational and performance claims should be attributed to that source rather than treated as independent evaluation.
#1 Best Overall
Where is AI being used in drug research?
Designing biologic candidates and screening molecular interactions
NVIDIA’s customer case says Amgen uses generative models to propose biologic candidate designs and predictive models to evaluate them, with BioNeMo and DGX Cloud among the tools described. This is a vendor-published account of a design-and-evaluation workflow; the case description does not establish a clinical outcome or an approved treatment.
NVIDIA’s Innophore case describes using Catalophore technology with GPU/cloud computing and BioNeMo to analyze molecular interactions and screen for off-target interactions. Innophore reported an average of 30% of experimentally determined alternative targets identified within its top ten ranked hits across 467 screened targets. That is a case-study result for a particular ranking task, not a general measure of drug-discovery accuracy or evidence that the ranked interactions cause harm in patients.
Rank #2
The same case reports that a protein–protein binding-affinity prediction computation that had taken 2,000 CPU hours was completed in 15 minutes at 5% of the original cost. This comparison applies to that specific workload, as reported by Innophore through NVIDIA; it is not a benchmark for all AI research or drug-discovery computing. The case page’s publication date is not stated.
The Tool Desk
Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Connecting laboratory biology to computation
Google Cloud describes Recursion’s platform as combining cellular experiments, image processing, neural networks, and cloud computing. Its case page reports five internal drugs advancing through clinical trials and more than 15 partner drugs in early discovery. These are time-sensitive pipeline figures from Recursion as reproduced by its cloud vendor; the case does not establish that AI alone caused those advances, and its publication date is not stated. Clinical-trial advancement is not the same as approval or proof of efficacy.
Supporting decisions across research and development
Microsoft’s October 4, 2024 customer story describes an Azure-based Novo Nordisk platform supporting regulatory affairs, early research, drug discovery, and trial design. Its described components include data and model discovery, a research copilot, reusable reasoning templates, auditability, and model-building infrastructure. Microsoft reports initial predictive-model results for cardiovascular risk. This is Microsoft’s account of a customer deployment, not an independent evaluation of the model or a claim that it discovered a medicine.
Novartis’s July 28, 2026 company account describes AI and digital tools for target selection, molecule assessment, clinical-trial design, processing information, and making earlier decisions. The company says its approach is task-focused, designed for reuse and scaling, human-centered, and supported by safety, quality, and privacy controls. Novartis also cites fewer than 10% of drug candidates historically reaching the market as background to its strategy; that figure is not a measured result of its AI deployment.
Retrieving scientific knowledge
In a September 14, 2026 account, Microsoft describes three organizational knowledge applications: Amgen’s Catalyst Copilot, Almirall’s AI research assistant, and UCB’s SKAI platform. The reported functions include retrieving institutional research knowledge and supporting enterprise use with protections for sensitive information. These tools can help staff find and use existing knowledge, but that workflow is distinct from evidence that a model designed a molecule or validated a drug candidate.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
Supporting clinical-trial operations
Accenture reports that Bristol Myers Squibb implemented more than 30 generative AI solutions and describes Workbench as an AI-enabled clinical-trial accelerator. Accenture’s case study says Workbench was adopted across more than 30 priority teams and had nearly 900 unique users after three months. Those are vendor-reported deployment and adoption measures, not measures of trial speed, drug efficacy, or patient outcomes. The case-study page’s publication date is not stated.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What does the broader evidence say about AI agents?
A May 2026 review by Huynh, Seal, and the AIA4S Consortium in Drug Discovery Today surveys agent applications including literature synthesis, protocol generation, toxicity prediction, small-molecule synthesis, drug repurposing, and wider decision workflows. It characterizes the field as early, so the review is a synthesis of possible and reported applications—not proof that every agent it discusses is a routine production system.
The review identifies data heterogeneity, system reliability, privacy, benchmarking, and real-world use as continuing challenges. Those issues matter because a system can produce a plausible answer while relying on incomplete or incompatible data, and performance on a selected benchmark may not transfer to a different laboratory, population, or decision. Human review and appropriate experimental or clinical validation remain essential.
How should you judge a claimed AI deployment?
Read a deployment claim by asking what the system actually did, what evidence supports the reported result, and how close that result is to a patient benefit. Keep scientific design, knowledge retrieval, computing infrastructure, and trial operations separate: success in one category does not prove success in another.
Recommended Free Tools
- Identify the task and stage. Is the system finding a target, ranking molecules, proposing a biologic, analyzing laboratory data, retrieving research records, or helping run a trial? Is it at target discovery, preclinical research, clinical development, or trial operations?
- Check what was measured. Look for the dataset or workload, denominator, comparison baseline, and outcome. “Top ten hits,” computing time, user adoption, and pipeline counts measure different things and should not be combined into one impact figure.
- Separate proposal from validation. A model-generated candidate is a hypothesis. Laboratory testing, clinical evidence, and regulatory review answer different questions; none should be inferred from a model ranking alone.
- Trace who is making the claim. Company and vendor case studies can explain a workflow and identify a deployment, but their performance claims are not automatically independent evaluations. Note when a vendor is repeating a customer’s figures.
- Look for human oversight and operational safeguards. Consider who reviews outputs, how sensitive data are protected, whether the system is auditable, and whether its performance can be reproduced outside the reported setting.
The cases described here do not establish a cross-company statistic showing that AI generally shortens drug discovery or improves clinical success. Their outcomes are too different—and their evidence sources too varied—to support a single overall “AI impact” percentage.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
